News
NSF-funded Smartphone COVID-19 Diagnostic Test Could Put Testing in the Hands of the Public
A smartphone diagnostic test for COVID-19 being developed by a University of Utah researcher holds the potential for quick, accurate testing without the need for individuals to go to a healthcare facility. A prototype may be ready within two...
News
BMS Research at ASCO Demonstrates Diverse Approaches in Treating Cancer to Improve Outcomes for Patients
Bristol Myers Squibb announced the presentation of data across its portfolio, aimed at addressing solid tumor and hematologic malignancies in 28 types of cancer, at the upcoming American Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program, which will...
News
HCATS, Apceth Expand Manufacturing Pact with Bluebird Bio
Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), have expanded their relationship with bluebird bio with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including:
Late stage drug product...
News
Thermo Fisher Scientific Announces SARS-CoV-2 GlobalAccess Sequencing Program
To accelerate national, multi-institutional efforts focused on mapping coronavirus transmission and epidemiological studies, Thermo Fisher Scientific announces the SARS-CoV-2 GlobalAccess Sequencing Program for research consortia and industry groups battling the spread of the pandemic globally. Under the program, the...
News
FDA Approves Eli Lilly Precision Oncology Treatment for Certain Lung and Thyroid Cancers
Eli Lilly is moving quickly to get a newly-approved precision oncology treatment for certain lung and thyroid cancers into the hands of patients.
Following U.S. Food and Drug Administration approval of Retevmo (selpercatinib) on Friday, Indianapolis-based Eli Lilly said it...
News
Enhertu granted Breakthrough Therapy Designation in the US for HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received...
News
Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of additional funding, on top of $4 million it invested in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















